Not yet recruiting
Naoxintong Capsule for Diabetic Nephropathy With Dampness Retention Pattern: A Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialAcronymNXT-DKD
NCT07698223· Phase 4· Chen Xiangmei· Source
Contact: Zheyi Dong, MD
Not yet recruiting
Drug-coated Balloons Versus Drug-eluting Stents for the Treatment of Femoropopliteal In-Stent Restenosis
NCT07277218· Chunshui He· Source
Contact: junjie chen
Not yet recruiting
Multi-center Study of Three-Dimensional Transesophageal Echocardiography in Patients With Secondary Mitral Regurgitation
NCT07918937· First Hospital of China Medical University· Source
Contact: Zhiqing Qiao (principal investigator)
Not yet recruiting
TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread
NCT07844187· Phase 1/2· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: XiuYing Xiao, Doctor
Not yet recruiting
A Multicenter Observational Study of Daridorexant in the Treatment of Insomnia
NCT07847021· Shanghai Mental Health Center· Source
Contact: Gang Wang
Recruiting
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
NCT07732309· Phase 1· Antengene Biologics Limited· Source
Contact: Xiaobing Wang
Recruiting
A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
NCT07653685· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: XiuYing Xiao, Doctor
Recruiting
A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
NCT07760454· Phase 1/2· UCARsgen Biotech Limited· Source
Contact: Juan Du
Not yet recruiting
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
NCT07760155· Phase 2· Shanghai Escugen Biotechnology Co., Ltd· Source
Contact: Qiong Fu
Not yet recruiting
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of PTT-621 in Patients With Moderately to Severely Active Ulcerative Colitis
NCT07747155· Phase 2· Pyrotech Therapeutics, Inc.· Source
Contact: Qi Lu
Not yet recruiting
Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer
NCT07683403· Phase 1/2· Fudan University· Source
Contact: Zizhen Zhang, Phd
Recruiting
ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management
NCT07517042· Shanghai Zhongshan Hospital· Source
Contact: Jing Ma, PhD
Recruiting
Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
NCT07552402· Harbin Medical University· Source
Contact: Xiuying Xiao
Recruiting
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
NCT07387549· Phase 3· Ipsen· Source
Contact: Ipsen Clinical Study Enquiries
Recruiting
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
NCT07571161· Phase 3· Eli Lilly and Company· Source
Contact: Gang Wang (principal investigator)
Recruiting
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
NCT07493135· Early phase 1· Suzhou Immunofoco Biotechnology Co., Ltd· Source
Contact: Juan Du
Recruiting
miRNA Panel for PCa Diagnosis
NCT07755592· RenJi Hospital· Source
Contact: Wei Xue, Phd
Recruiting
A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis
NCT07453004· Phase 2· TJ Biopharma Co., Ltd.· Source
Contact: Chunde Bao
Recruiting
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma
NCT07436949· Phase 1/2· Bambusa Therapeutics· Source
Contact: Jiping Li
Enrolling by invitation
Development and Validation of a Non-Invasive AI Diagnostic Model for Prostate Cancer Using Multiparametric MRI and PSMA PET/CT
NCT07690306· Xiangya Hospital of Central South University· Source
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· Phase 3· Eli Lilly and Company· Source
Contact: Wei Xue (principal investigator)
Recruiting
Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)
NCT07262645· Phase 3· Danyang Huichuang Medical Equipment Co., Ltd.· Source
Contact: Qun Xu, MD, PhD
Recruiting
HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer
NCT07232875· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source
Contact: Liwei Wang (principal investigator)
Recruiting
A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
NCT07208058· Phase 3· TJ Biopharma Co., Ltd.· Source
Contact: Qiong Fu
Recruiting
F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus
NCT07829614· Phase 1· Shandong New Time Pharmaceutical Co., LTD· Source
Contact: JZhang
Not yet recruiting
Mechanistic Studies of Chronic COPD Using Single-Cell Sequencing and Single-Cell Spatial Transcriptomics
NCT07208123· Tongji University· Source
Contact: Tang Jiang, Dr
Active, not recruiting
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
NCT07107256· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Recruiting
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
NCT07215663· Phase 1· Candid Therapeutics· Source
Contact: Liu Tian
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
NCT07044908· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: XiuYing Xiao, Doctor
Not yet recruiting
Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial
NCT07030621· Phase 3· RenJi Hospital· Source
Contact: Peiying Li MD,Ph.D
Recruiting
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
NCT06857214· Phase 1· Sichuan Baili Pharmaceutical Co., Ltd.· Source
Contact: Shuang Ye
Not yet recruiting
Deep Cervical Lymphaticovenous Anastomosis Surgery for Moderate-to-Advanced Dementia Patients
NCT06978946· RenJi Hospital· Source
Contact: Nan Zhi, MD
Recruiting
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis
NCT06857227· Phase 1· Sichuan Baili Pharmaceutical Co., Ltd.· Source
Contact: Shuang Ye
Recruiting
Lecanemab for Early Onset Familial Alzheimer's Disease
NCT06883019· RenJi Hospital· Source
Contact: Jinwen Xiao
Recruiting
The Efficacy of Gallium[68Ga]NOTA-DNA Multivalent SGC8 Injection for Bladder Tumour Imaging
NCT06763354· RenJi Hospital· Source
Contact: Di Jin
Recruiting
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
NCT06698796· Phase 3· Pfizer· Source
Not yet recruiting
An Exploratory Clinical Study Evaluating EPI-003 Injection for the Treatment of Chronic Hepatitis B
NCT06745973· Early phase 1· Epigenic Therapeutics, Inc· Source
Contact: YANG
Recruiting
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006· Phase 3· Shanghai Henlius Biotech· Source
Contact: Ying Li
Active, not recruiting
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
NCT06680921· Phase 3· Jiangsu Simcere Pharmaceutical Co., Ltd.· Source
Active, not recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153· Phase 3· Eli Lilly and Company· Source
Recruiting
Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy
NCT06090994· Phase 4· Fudan University· Source
Contact: Zhe Cui, PhD
Recruiting
DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
NCT06353126· Phase 4· RenJi Hospital· Source
Contact: Kang Associate chief physician
Recruiting
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
NCT06431490· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Maolan Li, Doctor
Recruiting
A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries
NCT06539689· FrontAce Scientific Co., Ltd· Source
Contact: Meng Ye
Recruiting
Clinical Study of HIFU for Localized Prostate Cancer
NCT06362577· RenJi Hospital· Source
Contact: Yanqing Wang
Active, not recruiting
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950· Phase 2· Takeda· Source
Recruiting
CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer
NCT06306612· RenJi Hospital· Source
Contact: Liang Dong, Dr.
Recruiting
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461· Phase 2· Takeda· Source
Contact: Zhi-jun Cao (principal investigator)
Recruiting
Obesity Queue Database
NCT06391320· RenJi Hospital· Source
Contact: Jiang Yue
Showing 50 of 57.